
    
      A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of
      eszopiclone 3 mg in women with insomnia secondary to perimenopause or menopause. Eligible
      subjects will be randomized to either eszopiclone 3 mg or placebo nightly for four weeks.
      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  